Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis

• Status: Recruiting
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
• Treatments: Hydroxychloroquine; Ivermectin

Criteria

Inclusion Criteria:

• Aged 18 - 70 years;

• Professionals working in areas of high exposure and high risk of transmission of SARS-COV-2;

• Understands and agrees to comply with planned study procedures;

• Signed informed consent for participation in the study.

Exclusion Criteria:

• Pregnancy or breastfeeding;

• Major allergy to Hidroxychloroquine, chloroquine or 4-aminoquinolines;

• Serum potassium lower than 3.4 mEq/l;

• Serum magnesium lower than 1.7 mg/dL;

• QTc interval > 470 ms for man and > 480 ms for woman;

• Weight < 40 kg;